Cargando…
Two patients walk into a clinic...a genomics perspective on the future of schizophrenia
Progress is being made in schizophrenia genomics, suggesting that this complex brain disorder involves rare, moderate to high-risk mutations and the cumulative impact of small genetic effects, coupled with environmental factors. The genetic heterogeneity underlying schizophrenia and the overlap with...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3214150/ https://www.ncbi.nlm.nih.gov/pubmed/22078159 http://dx.doi.org/10.1186/1741-7007-9-77 |
_version_ | 1782216210074566656 |
---|---|
author | Corvin, Aiden P |
author_facet | Corvin, Aiden P |
author_sort | Corvin, Aiden P |
collection | PubMed |
description | Progress is being made in schizophrenia genomics, suggesting that this complex brain disorder involves rare, moderate to high-risk mutations and the cumulative impact of small genetic effects, coupled with environmental factors. The genetic heterogeneity underlying schizophrenia and the overlap with other neurodevelopmental disorders suggest that it will not continue to be viewed as a single disease. This has radical implications for clinical practice, as diagnosis and treatment will be guided by molecular etiology rather than clinical diagnostic criteria. |
format | Online Article Text |
id | pubmed-3214150 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-32141502011-11-12 Two patients walk into a clinic...a genomics perspective on the future of schizophrenia Corvin, Aiden P BMC Biol Opinion Progress is being made in schizophrenia genomics, suggesting that this complex brain disorder involves rare, moderate to high-risk mutations and the cumulative impact of small genetic effects, coupled with environmental factors. The genetic heterogeneity underlying schizophrenia and the overlap with other neurodevelopmental disorders suggest that it will not continue to be viewed as a single disease. This has radical implications for clinical practice, as diagnosis and treatment will be guided by molecular etiology rather than clinical diagnostic criteria. BioMed Central 2011-11-11 /pmc/articles/PMC3214150/ /pubmed/22078159 http://dx.doi.org/10.1186/1741-7007-9-77 Text en Copyright ©2011 Corvin; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Opinion Corvin, Aiden P Two patients walk into a clinic...a genomics perspective on the future of schizophrenia |
title | Two patients walk into a clinic...a genomics perspective on the future of schizophrenia |
title_full | Two patients walk into a clinic...a genomics perspective on the future of schizophrenia |
title_fullStr | Two patients walk into a clinic...a genomics perspective on the future of schizophrenia |
title_full_unstemmed | Two patients walk into a clinic...a genomics perspective on the future of schizophrenia |
title_short | Two patients walk into a clinic...a genomics perspective on the future of schizophrenia |
title_sort | two patients walk into a clinic...a genomics perspective on the future of schizophrenia |
topic | Opinion |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3214150/ https://www.ncbi.nlm.nih.gov/pubmed/22078159 http://dx.doi.org/10.1186/1741-7007-9-77 |
work_keys_str_mv | AT corvinaidenp twopatientswalkintoaclinicagenomicsperspectiveonthefutureofschizophrenia |